Showing results (31-40 of 101) with videos related to
Sort By:
Pageof 11
JAMA Neurology|September 29, 2025
Menopause Impact on Multiple Sclerosis Disability ProgressionFrancesca Bridge, Paul G Sanfilippo, Chao Zhu, et al.Neurology|March 11, 2014
Fingolimod after natalizumab and the risk of short-term relapseVilija G Jokubaitis, Vivien Li, Tomas Kalincik, et al.International Journal of Molecular Sciences|August 26, 2023
DNA Methylation Signatures of Multiple Sclerosis Occur Independently of Known Genetic Risk and Are Primarily Attributed to B Cells and MonocytesAlexandre Xavier, Vicki E Maltby, Ewoud Ewing, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Journal of the Neurological Sciences|April 18, 2012
Increasing age at disability milestones among MS patients in the MSBase RegistryIlya Kister, Eric Chamot, Gary Cutter, et al.Journal of Neurology, Neurosurgery, and Psychiatry|October 19, 2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosisChao Zhu, Zhen Zhou, Izanne Roos, et al.The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Pageof 11